**Supplementary Table 2.** Patient demographics and baseline characteristics in the French cohort of the CORRELATE study, stratified by patient age at baseline.

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Age** | |  |
|  | **<65 years (n=107)** | **≥65 years (n=135)** | **Total (n=242)** |
| Age, median (range), years | 59 (39–64) | 71 (65–87) | 66 (39–87) |
| Male, n (%) | 60 (56.1) | 87 (64.4) | 147 (60.7) |
| ECOG performance status, n (%) |  |  |  |
| 0 | 36 (33.6) | 45 (33.3) | 81 (33.4) |
| 1 | 50 (46.7) | 70 (51.9) | 120 (49.6) |
| 2–4 | 8 (7.5) | 12 (8.9) | 20 (8.3) |
| missing | 13 (12.2) | 8 (5.9) | 21 (8.7) |
| *KRAS* mutation, n (%) |  |  |  |
| Yes  No  Unknown | 45 (42.1)  54 (50.5)  8 (7.5) | 66 (47.4)  64 (47.4)  5 (3.7) | 111 (45.9)  118 (48.8)  13 (5.4) |
| *BRAF* mutation, n (%) |  |  |  |
| Yes  No  Unknown | 7 (6.5)  71 (66.4)  29 (27.1) | 6 (4.4)  85 (63.0)  44 (32.6) | 13 (5.4)  156 (64.5)  73 (30.2) |
| NRAS mutation, n (%) |  |  |  |
| Yes  No  Unknown | 7 (6.5)  60 (56.1)  40 (37.4) | 11 (8.2)  55 (40.7)  69 (51.1) | 18 (7.4)  115 (47.5)  109 (45.0) |
| Main metastatic sites at regorafenib start, n (%) |  |  |  |
| liver | 86 (80.4) | 102 (75.6) | 188 (77.7) |
| lung | 70 (65.4) | 84 (62.2) | 154 (63.6) |
| peritoneum | 18 (16.8) | 17 (12.6) | 35 (14.5) |
| bone | 15 (14.0) | 8 (5.9) | 23 (9.5) |